JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ as the first and only endothelin receptor...

Related Keywords

Liechtenstein ,Switzerland ,Norway ,Allschwil ,Switzerland General ,Iceland ,United States ,Australia ,Swiss ,America ,Americans ,Jean Paul Clozel ,Clozelm Aprocitentan ,J Physiol Pharmacol ,Andrewc Weiss ,European Medicines Agency ,European Commission ,European Union ,Committee For Medicinal Products Human Use ,Swiss Exchange ,Drug Administration ,European Union Member States ,Idorsia Ltd ,Idorsia Pharmaceuticals Ltd ,Committee For Medicinal Products Human ,Head Of Investor Relations Corporate Communications ,Medicinal Products ,Human Use ,Paul Clozel ,Chief Executive Officer ,African Americans ,North America ,European Economic Area ,Northern Ireland ,Factor Collaboration ,Pharmacol Exp ,Clin Endocrinol ,American College ,American Heart Association Task Force ,Dose Response Study ,Clin Hypertension ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,Markets ,